Trials / Completed
CompletedNCT06631430
A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men
Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3810477 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3810477 in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 3810477 | BI 3810477 formulation A |
| DRUG | BI 3810477 | BI 3810477 formulation B |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-10-30
- Primary completion
- 2025-06-12
- Completion
- 2025-06-12
- First posted
- 2024-10-08
- Last updated
- 2025-06-18
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06631430. Inclusion in this directory is not an endorsement.